
DLA Piper Life Sciences Summit
Wednesday, October 4, 2023
9:00 am - 5:00 pm ET
Reception to follow
DLA Piper’s inaugural Life Sciences Summit will take place on Wednesday, October 4 in New York City. The summit will bring together pharmaceutical, biotechnology, and medical device companies from around the world and at all stages of the life cycle to discuss emerging trends and challenges facing the industry.
DLA Piper’s life sciences team will lead discussions with our clients on diverse topics of interest to high-level lawyers involved in a wide array of issues facing the industry, including:
- Political and legal challenges facing the life sciences industry
- The future of drug pricing in the wake of the Inflation Reduction Act
- Protecting your intellectual property around the world in an ever-changing patent landscape, including the Unified Patent Court and beyond
- The current state of financing and M&A for life sciences companies
- Challenges life sciences companies face when expanding and doing business around the world
- The legal challenges raised by the rapid expansion of artificial intelligence
- FDA regulation of new medical technologies
Location
etc.venues 360 Madison
360 Madison Avenue
5th Floor
New York, NY 10017
Directions
For more information
Please contact Shannon Tomassi with questions.
CLE Information
DLA Piper LLP (US) has been certified by the State Bar of California, Illinois MCLE Board, the Board on Continuing Legal Education of the Supreme Court of New Jersey, and the New York State Continuing Legal Education Board as an Accredited Provider. The following CLE credit is being sought:
- California: 2.25 Credit (2.25 General, 0.0 Ethics)
- Illinois: 2.25 Credit (2.25 General, 0.0 Professional Responsibility)
- New Jersey: 2.7 Credits (2.7 General, 0.0 Ethics)
- New York: 2.5 Transitional & Non-Transitional Credit (2.5 Professional Practice, 0.0 Ethics)
CLE credit will be applied for in other states where DLA Piper has an office with the exception of Minnesota, North Carolina, Pennsylvania, and Puerto Rico.
Speakers
Anne Baker Director of Legal Affairs, Regulatory, Quality & Compliance Dexcom |
Subin Baral Global Deals Leader, Life Sciences Ernst & Young |
|
John A. Bardi SVP, Market Access, Policy and Government Affairs Intra-Cellular Therapies |
Karen Day Senior Counsel Pfizer |
|
Michael Haughney Director, Global Compliance Monitoring and Analytics Bristol Myers Squibb |
Chris Jewell SVP and General Counsel Taiho Oncology |
|
Monaya Krause Chief Global Regulatory Counsel GE HealthCare |
Brian O'Callaghan CEO and Board Member Deep Genomics |
|
Kenneth Peist VP, Intellectual Property Dermavant Sciences |
Angela Riemer SVP, Global Policy & Public Affairs Pfizer |
|
Philip Ross Global Chairman J.P. Morgan Healthcare Investment Banking |
Aviva Wein Assistant General Counsel, Products Liability Johnson & Johnson |
|
Dr. Chen-Sen "Samson" Wu General Counsel, Patient Care Solutions GE HealthCare |
DLA Piper Speakers
Agenda
9:00 am - Registration and breakfast
10:00 am - Introductory remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice
10:05 am - Political and legal challenges facing the life sciences industry
Former Senator Richard Burr and former Congressman Jim Greenwood
10:50 am - The future of drug pricing in the wake of the Inflation Reduction Act
Kirsten Axelsen, John Bardi (Intra-Cellular Therapies), Rachel Portman, Angela Riemer (Pfizer)
11:35 am - Protecting your IP around the world in the era of an ever-changing patent landscape: The UPC and beyond
Gualtiero Dragotti, Nicole Endejann, Chris Jewell (Taiho Oncology), Amy Lydon (Medtronic), Kenneth Peist (Dermavant Sciences)
12:20 pm - Lunch and networking
1:20 pm - The market for innovation: Current state of life sciences financings and M&A
Andy Gilbert, Philip Ross (J.P. Morgan Healthcare Investment Banking)
2:20 pm - Strategies for Companies Expanding Globally
Jeff Baglio, Subin Baral (Ernst & Young), Maruti Narayan, Brian O'Callaghan (Deep Genomics), Victoria Rhodes
3:05 pm - Coffee and cookies break
3:25 pm - The rise of big data: Legal challenges raised by artificial intelligence and other data science trends
Michael Haughney (Bristol Myers Squibb), Danny Tobey, Aviva Wein (Johnson & Johnson), Dr. Chen-Sen "Samson" Wu (GE HealthCare)
4:10 pm - FDA regulation of new medical technologies
Anne Baker (Dexcom), Karen Day (Pfizer), Perham Gorji, Monaya Krause (GE HealthCare), Geoffrey Levitt, Keo Shaw
4:55 pm - Closing remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice
5:00 pm - Cocktail reception